Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-277 · 1 trial · 1 indication
Cmax of ABBV-277
Tmax of ABBV-277
Terminal phase elimination rate constant (beta) of ABBV-277
Terminal phase elimination half-life of ABBV-277
AUCt of ABBV-277
AUCinf of ABBV-277
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study
| Arm | Type | Description |
|---|---|---|
| Group 1: ABBV-277-Dose A | EXPERIMENTAL | Participants will receive ABBV-277 Dose A on day 1 and followed for 196 days |
| Group 1: Placebo | EXPERIMENTAL | Participants will receive Placebo on day 1 and followed for 196 days |
| Group 2: ABBV-277-Dose B | EXPERIMENTAL | Participants will receive ABBV-277 Dose B on day 1 and followed for 196 days |
| Group 2: Placebo | EXPERIMENTAL | Participants will receive Placebo on day 1 and followed for 196 days |
| Group 3: ABBV-277-Dose C | EXPERIMENTAL | Participants will receive ABBV-277 Dose C on day 1 and followed for 196 days |
| Group 3: Placebo | EXPERIMENTAL | Participants will receive Placebo on day 1 and followed for 196 days |
| Group 4: ABBV-277-Dose D | EXPERIMENTAL | Participants will receive ABBV-277 Dose D on day 1 and followed for 196 days |
| Group 4: Placebo | EXPERIMENTAL | Participants will receive Placebo on day 1 and followed for 196 days |
| Group 5: ABBV-277-Dose E | EXPERIMENTAL | Participants will receive ABBV-277 Dose E on day 1 and day 2 and followed for 196 days |
| Group 5: Placebo | EXPERIMENTAL | Participants will receive Placebo on day 1 and day 2 and followed for 196 days |
| Name | Type | Description |
|---|---|---|
| ABBV-277 | DRUG | • Intravenous (IV) infusion |
| Placebo | DRUG | • Intravenous (IV) infusion |
Inclusion Criteria: * Body weight ≥ 35 kg * Body Mass Index (BMI) is ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile neurological examination, and ...
ABBV-277 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its safety, tolerability, pharmacokinetics, and immunogenicity in healthy adult participants. It is not approved for any medical condition.
ABBV-277 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical research on this investigational small molecule in healthy volunteers.
ABBV-277 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. A single Phase 1 trial has been completed, and the drug remains in early-stage clinical research.
ABBV-277 has one completed Phase 1 clinical trial, registered as NCT07136103. This study evaluated the safety, tolerability, pharmacokinetics, and immunogenicity of ABBV-277 in healthy adult participants in the United States. The trial enrolled 32 participants and was randomized, double-blind, and controlled.
ABBV-277 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial in healthy volunteers was designed to assess safety and tolerability, but the drug has not received marketing approval for any indication.